Nurix Therapeutics Inc. (NRIX)
NASDAQ: NRIX
· Real-Time Price · USD
12.15
0.07 (0.58%)
At close: Jun 04, 2025, 3:59 PM
Nurix Therapeutics Revenue Breakdown
| Period Ending | Nov 30, 2024 | Nov 30, 2023 |
|---|---|---|
| Collaboration Revenue Revenue | 54.55M | 56.99M |
| Collaboration Revenue Revenue Growth | -4.28% | n/a |
Operating Expense Breakdown
| Period Ending | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 | Aug 31, 2023 | May 31, 2023 | Feb 28, 2023 | Nov 30, 2022 | Aug 31, 2022 | May 31, 2022 | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 | Nov 30, 2020 | Aug 31, 2020 | May 31, 2020 | Feb 29, 2020 | Nov 30, 2019 | Aug 31, 2019 | May 31, 2019 | Feb 28, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 11.65M | 10.72M | 11.72M | 9.95M | 9.96M | 8.96M | 10.62M | 11.68M | 9.82M | 9.37M | 9.75M | 9.65M | 9.23M | 8.82M | 8.34M | 7.51M | 6.53M | 6.25M | 4.34M | 3.27M | 2.45M | 2.6M | 2.18M | 1.87M | 1.67M |
| Selling, General, and Administrative Revenue Growth | +8.74% | -8.54% | +17.78% | -0.07% | +11.15% | -15.68% | -9.03% | +18.91% | +4.85% | -3.91% | +0.97% | +4.62% | +4.65% | +5.69% | +11.08% | +15.02% | +4.45% | +44.12% | +32.66% | +33.47% | -5.84% | +19.14% | +16.79% | +11.98% | n/a |
| Research and Development Revenue | 69.66M | 67.22M | 55.48M | 46.59M | 47.96M | 47.78M | 47.86M | 45.76M | 45.82M | 46.11M | 47.76M | 47.49M | 43.14M | 36.53M | 30.91M | 25.99M | 23M | 20.45M | 18.94M | 14.14M | 12.97M | 12.82M | 11.01M | 10.76M | 10.43M |
| Research and Development Revenue Growth | +3.63% | +21.17% | +19.08% | -2.85% | +0.38% | -0.16% | +4.57% | -0.12% | -0.63% | -3.47% | +0.56% | +10.10% | +18.08% | +18.20% | +18.90% | +13.00% | +12.51% | +7.95% | +33.92% | +9.06% | +1.12% | +16.50% | +2.31% | +3.11% | n/a |